Skip Nav Destination
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS|
November 20, 2025
Isatuximab for relapsed AL amyloidosis Free
CME
Blood (2025) 146 (21): 2615.
Connected Content
A related article has been published:
Isatuximab for relapsed and/or refractory AL amyloidosis: results of a prospective phase 2 trial (SWOG S1702)
Citation
Isatuximab for relapsed AL amyloidosis. Blood 2025; 146 (21): 2615. doi: https://doi.org/10.1182/blood.2025031732
Download citation file:
November 20 2025
Advertisement intended for health care professionals
Cited By
Advertisement intended for health care professionals
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal